idursulfase
Sign in to saveAlso known as Alpha-L-iduronate sulfate sulfatase, Iduronate 2-sulfatase, EC 3.1.6.13, Iduronate-2-sulfatase, IDS, IPR035874
Idursulfase (brand name Elaprase), manufactured by Takeda, is a drug used to treat Hunter syndrome (also called MPS-II). It is a purified form of iduronate-2-sulfatase, a lysosomal enzyme, and is produced by recombinant DNA technology in a human cell line.
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Enzyme
- First approval
- 2006
- Admin. routes
- parenteral
- Indications
- mucopolysaccharidosis type 2, mucopolysaccharidosis
via ChEMBL · EBI
Wikidata facts
- Part of
- iduronate-2-sulfatase
- Has use
- medication
Show 5 more facts
- EC enzyme number
- 3.1.6.13
- medical condition treated
- mucopolysaccharidosis II
- has characteristic
- biopharmaceutical
- subject has role
- enzyme
- legal status (medicine)
- boxed warning
Sources (3)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- References
- External links
Idursulfase (brand name Elaprase), manufactured by Takeda, is a drug used to treat Hunter syndrome (also called MPS-II). It is a purified form of iduronate-2-sulfatase, a lysosomal enzyme, and is produced by recombinant DNA technology in a human cell line.
It is one of the most expensive drugs ever produced, costing US$567,412 per patient per year.
Excerpted from Wikipedia’s “idursulfase” article, available under the CC BY-SA 4.0 licence.
Available in 14 languages
via Wikidata sitelinks · CC0